Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Viruses. 2010 Dec;2(12):2803-30. doi: 10.3390/v2122803. Epub 2010 Dec 22.

Cidofovir Activity against Poxvirus Infections.

Author information

  • 1Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KULeuven, Minderboredersstraat 10, B-3000 Leuven, Belgium; E-Mail: robert.snocek@rega.kuleuven.be.

Abstract

Cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, HPMPC] is an acyclic nucleoside analog approved since 1996 for clinical use in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. Cidofovir (CDV) has broad-spectrum activity against DNA viruses, including herpes-, adeno-, polyoma-, papilloma- and poxviruses. Among poxviruses, cidofovir has shown in vitro activity against orthopox [vaccinia, variola (smallpox), cowpox, monkeypox, camelpox, ectromelia], molluscipox [molluscum contagiosum] and parapox [orf] viruses. The anti-poxvirus activity of cidofovir in vivo has been shown in different models of infection when the compound was administered either intraperitoneal, intranasal (aerosolized) or topically. In humans, cidofovir has been successfully used for the treatment of recalcitrant molluscum contagiosum virus and orf virus in immunocompromised patients. CDV remains a reference compound against poxviruses and holds potential for the therapy and short-term prophylaxis of not only orthopox- but also parapox- and molluscipoxvirus infections.

KEYWORDS:

acyclic nucleoside analog; cidofovir; poxviruses

PMID:
21994641
[PubMed]
PMCID:
PMC3185586
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
    Loading ...
    Write to the Help Desk